Administration of epigallocatechin-3-gallate for microdermabrasion
| Autor: | Z R KHISMATULLINA |
|---|---|
| Rok vydání: | 2010 |
| Předmět: | |
| Zdroj: | Vestnik dermatologii i venerologii. 86:99-103 |
| ISSN: | 2313-6294 0042-4609 |
| DOI: | 10.25208/vdv864 |
| Popis: | Rationale of the study As previously demonstrated, epigallocatechin-3-gallate (EGCG) accelerates the formation of the collagenous matrix and at the same time prevents any extraordinary collagen synthesis in the course of wound healing. In addition, EGCG is one of the most potent antioxidants and can inhibit cyclooxygenase-2, which in general lays the basis for studying the possibility to use it as an anti-inflammatory drug after dermabrasion procedures as well as to prevent pathologic cicatrization. Materials and methods. Forty women were divided into two groups (21 patients in the group treated with Egallohit, 10% EGCG, and 19 patients treated with Pantoderm Cream, 5% dexpanthenol). The drugs were applied twice a day for 50 days. Dermabrasion was performed on Days 1, 12 and 24. The patients were examined at Days 3, 15, 27, 36 and 60 of the treatment. Each of them filled in a questionnaire about the facial skin pain and itching. The facial skin humidity, fatness and pigmentation as well as number and depth of wrinkles were also measured. The total skin photodegradation index (by a blinded appraiser) was also assessed at the first and last visit. Results. No statistically significant differences in the number and depth of wrinkles, intensity and duration of facial skin pain and itching as well as skin photodegradation index between the groups both prior to and after the treatment were revealed. Conclusions. EGCG (10% Egallohit Gel) is as efficient for skin protection after microdermabrasion procedures as conventional drugs (5% cream with dexpanthenol). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|